DDA implements ban on production of 10 drugs based on committee recommendations

KATHMANDU: The production of 10 different drug types has been banned by the Department of Drug Administration (DDA), as per recommendations from the Drug Evaluation Committee.

In an official notice, Narayan Dhakal, the Director-General of the DDA, specified that the prohibited drugs include linagliptin 2.5 mg, linagliptin 10 mg, rivaroxaban 5 mg, aceclofenac 200 mg, and aceclofenac 300 mg.

Moreover, the production of combinations such as linagliptin 2.5 mg with metformin 500 mg, linagliptin 2.5 mg with metformin 850 mg, linagliptin 5 mg with metformin 500 mg, and linagliptin 5 mg with metformin 850 mg is also currently restricted. Notably, these medications are manufactured by Nepali companies.

Director-General Dhakal indicated that further decisions regarding these bans will be determined in the upcoming Medicines Advisory Committee meeting.

Additionally, the DDA has issued instructions against the production of new products and the expansion of production for existing brands in the market until recommendations are received from the pharmaceutical advisory committee.